Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

60 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Rosiglitazone decreases albuminuria in type 2 diabetic patients.
Miyazaki Y, Cersosimo E, Triplitt C, DeFronzo RA. Miyazaki Y, et al. Kidney Int. 2007 Dec;72(11):1367-73. doi: 10.1038/sj.ki.5002516. Epub 2007 Sep 5. Kidney Int. 2007. PMID: 17805239 Clinical Trial.
Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients.
Miyazaki Y, Glass L, Triplitt C, Matsuda M, Cusi K, Mahankali A, Mahankali S, Mandarino LJ, DeFronzo RA. Miyazaki Y, et al. Diabetologia. 2001 Dec;44(12):2210-9. doi: 10.1007/s001250100031. Diabetologia. 2001. PMID: 11793023 Clinical Trial.

Patients received 75 g OGTT and two-step euglycaemic insulin (40 and 160 mU/m(2)min) clamp with 3-(3)H-glucose, (14)C-palmitate and indirect calorimetry. RESULTS: After 12 weeks, rosiglitazone reduced fasting plasma glucose (195 +/- 11 to 150 +/- 7 mg/dl, p < 0.01), mea

Patients received 75 g OGTT and two-step euglycaemic insulin (40 and 160 mU/m(2)min) clamp with 3-(3)H-glucose, (14)C-palmitate and i …
Abdominal fat distribution and peripheral and hepatic insulin resistance in type 2 diabetes mellitus.
Miyazaki Y, Glass L, Triplitt C, Wajcberg E, Mandarino LJ, DeFronzo RA. Miyazaki Y, et al. Am J Physiol Endocrinol Metab. 2002 Dec;283(6):E1135-43. doi: 10.1152/ajpendo.0327.2001. Am J Physiol Endocrinol Metab. 2002. PMID: 12424102 Clinical Trial.
Exenatide: from the Gila monster to the pharmacy.
Triplitt C, Chiquette E. Triplitt C, et al. J Am Pharm Assoc (2003). 2006 Jan-Feb;46(1):44-52; quiz 53-5. doi: 10.1331/154434506775268698. J Am Pharm Assoc (2003). 2006. PMID: 16529340 Review.
Comparison of glargine insulin versus rosiglitazone addition in poorly controlled type 2 diabetic patients on metformin plus sulfonylurea.
Triplitt C, Glass L, Miyazaki Y, Wajcberg E, Gastaldelli A, De Filippis E, Cersosimo E, DeFronzo RA. Triplitt C, et al. Diabetes Care. 2006 Nov;29(11):2371-7. doi: 10.2337/dc06-0564. Diabetes Care. 2006. PMID: 17065670 Clinical Trial.
First approved inhaled insulin therapy for diabetes mellitus.
Jani R, Triplitt C, Reasner C, Defronzo RA. Jani R, et al. Expert Opin Drug Deliv. 2007 Jan;4(1):63-76. doi: 10.1517/17425247.4.1.63. Expert Opin Drug Deliv. 2007. PMID: 17184163 Review.
New technologies and therapies in the management of diabetes.
Triplitt CL. Triplitt CL. Am J Manag Care. 2007 Apr;13 Suppl 2:S47-54. Am J Manag Care. 2007. PMID: 17417933 Review.
Addition of pioglitazone and ramipril to intensive insulin therapy in type 2 diabetic patients improves vascular dysfunction by different mechanisms.
Fernandez M, Triplitt C, Wajcberg E, Sriwijilkamol AA, Musi N, Cusi K, DeFronzo R, Cersosimo E. Fernandez M, et al. Diabetes Care. 2008 Jan;31(1):121-7. doi: 10.2337/dc07-0711. Epub 2007 Oct 1. Diabetes Care. 2008. PMID: 17909084 Clinical Trial.
60 results
Jump to page
Feedback